Can genome engineering be used to target cancer-associated enhancers?

Epigenomics

Volumn 6, Issue 5, 2014, Pages 493-501

  Grimmer, Matthew R ^a   Farnham, Peggy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CRISPRs; DNA methylation; enhancers; epigenetic therapy; gene expression; genome engineering; genomic nuclease; histone modifications; TALENs; ZFNs

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; BACTERIAL DNA; CYTOSINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; GUIDE RNA; HISTONE ACETYLTRANSFERASE; HISTONE METHYLTRANSFERASE; NUCLEASE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER NUCLEASE; ZINC FINGER PROTEIN; PROTEIN BINDING;

ARTICLE; BINDING SITE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA METHYLATION; DNA RNA HYBRIDIZATION; ENHANCER REGION; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC ENGINEERING; GENETIC MANIPULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN GENOME; NEOPLASM; NONHUMAN; ONCOGENE MYC; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ANIMAL; ANTIBODY SPECIFICITY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOMICS; METABOLISM; PROCEDURES; REGULATORY SEQUENCE;

ANIMALS; BINDING SITES; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ENGINEERING; GENOMICS; HUMANS; NEOPLASMS; ORGAN SPECIFICITY; PROTEIN BINDING; REGULATORY SEQUENCES, NUCLEIC ACID;

EID: 84913608232     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.30     Document Type: Article

References (70)

1. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell 152(6), 1237-1251 (2013).
2. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifcations as therapeutic targets. Nat. Biotechnol. 28 (10), 1069-1078 (2010).
3. Portela A, Esteller M. Epigenetic modifcations and human disease. Nat. Biotechnol. 28 (10), 1057-1068 (2010).
4. Pennacchio LA, Bickmore W, Dean A, Nobrega MA, Bejerano G. Enhancers: fve essential questions. Nat. Rev. Genet. 14(4), 288-295 (2013).
5. Calo E, Wysocka J. Modifcation of enhancer chromatin: what, how, and why? Mol. Cell 49(5), 825-837 (2013).
6. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489 (7414), 57-74 (2012).
7. Ong C-T, Corces VG. Enhancer function: new insights into the regulation of tissue-specifc gene expression. Nat. Rev. Genet. 12(4), 283-293 (2011).
8. Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 14(3), R21 (2013).
9. Kieffer-Kwon KR, Tang Z, Mathe E et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell 155 (7), 1507-1520 (2013).
10. Ziller MJ, Gu H, Müller F et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500(7463), 477-481 (2013).
11. Hazelett DJ, Rhie SK, Gaddis M et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 10 (1), e1004102 (2014).
12. Jia L, Landan G, Pomerantz M et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 5(8), e1000597 (2009).
13. Lupien M, Eeckhoute J, Meyer CA et al. Foxa1 translates epigenetic signatures into enhancer-driven lineage-specifc transcription. Cell 132(6), 958-970 (2008).
14. Lovén J, Hoke HA, Lin CY et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153(2), 320-334 (2013).
15. Whyte WA, Orlando DA, Hnisz D et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153(2), 307-319 (2013).
16. Kim TK, Hemberg M, Gray JM et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 465(7295), 182-187 (2010).
17. Kim T, Cui R, Jeon YJ et al. Long-range interaction and correlation between myc enhancer and oncogenic long noncoding rna carlo-5. Proc. Natl Acad. Sci. USA 111(11), 4173-4178 (2014).
18. Mousavi K, Zare H, Dell'Orso S et al. Ernas promote transcription by establishing chromatin accessibility at defned genomic loci. Mol. Cell 51(5), 606-617 (2013).
19. Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 31(11), 536-546 (2010).
20. Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z, Xu W. Progress of HDAC inhibitor panobinostat in the treatment of cancer. Curr. Drug Targets 15(6), 622-634 (2014).
21. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124(1), 30-39 (2014).
22. Eguchi M, Nguyen C, Lee SC, Kahn M. Icg-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med. Chem. 1(5), 467-472 (2005).
23. Sur IK, Hallikas O, Vähärautio A et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science 338(6112), 1360-1363 (2012).
24. Wasylishen AR, Penn LZ. Myc: the beauty and the beast. Genes Cancer 1(6), 532-541 (2010).
25. Grisanzio C, Freedman ML. Chromosome 8q24-associated cancers and myc. Genes Cancer 1(6), 555-559 (2010).
26. Ramirez CL, Foley JE, Wright DA et al. Unexpected failure rates for modular assembly of engineered zinc fngers. Nat. Methods 5(5), 374-375 (2008).
27. Bogdanove AJ, Voytas DF. Tal effectors: customizable proteins for DNA targeting. Science 333(6051), 1843-1846 (2011).
28. Cermak T, Doyle EL, Christian M et al. Effcient design and assembly of custom talen and other tal effector-based constructs for DNA targeting. Nucleic Acids Res. 39(12), e82 (2011).
29. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by tal effectors. Science 326(5959), 1501 (2009).
30. Mali P, Yang L, Esvelt KM et al. RNA-guided human genome engineering via cas9. Science 339(6121), 823-826 (2013).
31. Segal DJ, Meckler JF. Genome engineering at the dawn of the golden age. Annu. Rev. Genomics Hum. Genet. 14(1), 135-158 (2013).
32. Miller JC, Holmes MC, Wang J et al. An improved zinc-fnger nuclease architecture for highly specifc genome editing. Nat. Biotechnol. 25(7), 778-785 (2007).
33. Lee HJ, Kim E, Kim JS. Targeted chromosomal deletions in human cells using zinc fnger nucleases. Genome Res. 20(1), 81-89 (2010).
34. Perez-Pinera P, Kocak DD, Vockley CM et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 10 (10), 973-976 (2013).
35. Method of the Year 2011. Nat. Methods 9(1), 1 (2012).
36. Webster DE, Barajas B, Bussat RT et al. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition. Genome Res. 24(5), 751-760 (2014).
37. Ochiai H, Miyamoto T, Kanai A et al. TALEN-mediated single-base-pair editing identifcation of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. Proc. Natl Acad. Sci. USA 111(4), 1461-1466 (2014).
38. Rivenbark AG, Stolzenburg S, Beltran AS et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 7(4), 350-360 (2012).
39. Maeder ML, Angstman JF, Richardson ME et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 31(12), 1137-1142 (2013).
40. Chen H, Kazemier HG, De Groote ML, Ruiters MHJ, Xu GL, Rots MG. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 42 (3), 1563-1574 (2013).
41. Mendenhall EM, Williamson KE, Reyon D et al. Locus-specifc editing of histone modifcations at endogenous enhancers. Nat. Biotechnol. 31(12), 1133-1136 (2013).
42. Stolzenburg S, Rots MG, Beltran AS et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res. 40(14), 6725-6740 (2012).
43. Perez-Pinera P, Ousterout DG, Brunger JM et al. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat. Methods 10(3), 239-242 (2013).
44. Gilbert LA, Larson MH, Morsut L et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154(2), 442-451 (2013).
45. Konermann S, Brigham MD, Trevino A et al. Optical control of mammalian endogenous transcription and epigenetic states. Nature 500(7463), 472-476 (2013).
46. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343(6166), 80-84 (2014).
47. Mali P, Aach J, Stranges PB et al. Cas9 transcriptional activators for target specifcity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31(9), 833-838 (2013).
48. Cho SW, Kim S, Kim Y et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24(1), 132-141 (2014).
49. Hou Z, Zhang Y, Propson NE et al. Effcient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl Acad. Sci. USA 110 (39), 15644-15649 (2013).
50. Cong L, Ran FA, Cox D et al. Multiplex genome engineering using CRISPR/Cas systems. Science339(6121), 819-823 (2013).
51. Brayer KJ, Kulshreshtha S, Segal DJ. The protein-binding potential of C2H2 zinc fnger domains. Cell Biochem. Biophys. 51(1), 9-19 (2008).
52. Persikov AV, Singh M. An expanded binding model for Cys2His2 zinc fnger protein-DNA interfaces. Phys. Biol. 8(3), 035010 (2011).
53. Lam KN, Van Bakel H, Cote AG, Van Der Ven A, Hughes TR. Sequence specifcity is obtained from the majority of modular C2H2 zinc-fnger arrays. Nucleic Acids Res. 39(11), 4680-4690 (2011).
54. Wolfe SA, Grant RA, Elrod-Erickson M, Pabo CO. Beyond the "recognition code": structures of two Cys2His2 zinc fnger/TATA box complexes. Structure 9 (8), 717-723 (2001).
55. Miller JC, Tan S, Qiao G et al. A tale nuclease architecture for effcient genome editing. Nat. Biotechnol. 29(2), 143-148 (2011).
56. Grimmer MR, Stolzenburg S, Ford E, Lister R, Blancafort P, Farnham PJ. Analysis of an artifcial zinc fnger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res. 42(16), 10856-10868 (2014).
57. Deng D, Yan C, Wu J, Pan X, Yan N. Revisiting the tale repeat. Protein Cell 5(4), 297-306 (2014).
58. Sun N, Bao Z, Xiong X, Zhao H. SunnyTALEN: a second-generation TALEN system for human genome editing. Biotechnol. Bioeng. 111(4), 683-691 (2014).
59. Wu X, Scott DA, Kriz AJ et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 32(7), 670-676 (2014).
60. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specifcity using truncated guide RNAs. Nat. Biotechnol. 32(3), 279-284 (2014).
61. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife 29(2), e00471 (2013).
62. Hsu PD, Scott DA, Weinstein JA et al. DNA targeting specifcity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31(9), 827-832 (2013).
63. Xiao A, Cheng Z, Kong L et al. CasOT: a genome-wide Cas9/gRNA off-target searching tool. Bioinformatics doi:10.1093btt764 (2014) (Epub ahead of print).
64. Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30(10), 1473-1475 (2014).
65. Ran FA, Hsu PD, Lin CY et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specifcity. Cell 154(6), 1380-1389 (2013).
66. Huang Q, Gong C, Li J et al. Distance and helical phase dependence of synergistic transcription activation in cis-regulatory module. PLoS One 7(1), e31198 (2012).
67. Li L, Krymskaya L, Wang J et al. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc fnger nucleases. Mol. Ther. 21(6), 1259-1269 (2013).
68. Lara H, Wang Y, Beltran AS et al. Targeting serous epithelial ovarian cancer with designer zinc fnger transcription factors. J. Biol. Chem. 287(35), 29873-29886 (2012).
69. Liu J, Gaj T, Patterson JT, Sirk SJ, Barbas CF. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One 9(1), e85755 (2014).
70. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater. 24(28), 3747-3756 (2012).